Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease

NCT03486938 is registered in ClinicalTrials.gov with AgeneBio as lead sponsor.

NCT NCT03486938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03486938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
Lead sponsor
AgeneBio
Phase
Phase 2/3
Overall status
Completed
Start date
December 13, 2018
Completion date
November 2, 2022
Enrollment
164 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

mild cognitive impairment, prodromal alzheimer's disease